|
JP6898868B2
(ja)
*
|
2015-06-25 |
2021-07-07 |
ユニバーシティー ヘルス ネットワーク |
Ｈｐｋ１阻害剤およびそれを用いる方法
|
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
|
AR109595A1
(es)
|
2016-09-09 |
2018-12-26 |
Incyte Corp |
Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
|
|
TWI771319B
(zh)
|
2016-09-09 |
2022-07-21 |
美商英塞特公司 |
吡唑并吡啶化合物及其用途
|
|
WO2018049214A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
|
WO2018152220A1
(en)
*
|
2017-02-15 |
2018-08-23 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
CN110402248B
(zh)
|
2017-03-15 |
2023-01-06 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的氮杂吲哚类
|
|
US10407424B2
(en)
|
2017-03-30 |
2019-09-10 |
Genentech, Inc. |
Naphthyridines as inhibitors of HPK1
|
|
MX2019010302A
(es)
*
|
2017-03-30 |
2019-11-21 |
Hoffmann La Roche |
Isoquinolinas como inhibidores de hpk1.
|
|
CA3066859A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
WO2018228923A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
|
US20200246347A1
(en)
|
2017-06-13 |
2020-08-06 |
Bayer Pharma Aktiengesellschaft |
Substituted Pyrrolopyridine-Derivatives
|
|
WO2019016071A1
(en)
|
2017-07-18 |
2019-01-24 |
Bayer Pharma Aktiengesellschaft |
SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES
|
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
|
CN109721620B
(zh)
*
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
|
KR102808367B1
(ko)
*
|
2017-11-06 |
2025-05-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Hpk1 억제제로서 유용한 이소푸라논 화합물
|
|
US10800761B2
(en)
*
|
2018-02-20 |
2020-10-13 |
Incyte Corporation |
Carboxamide compounds and uses thereof
|
|
WO2019164847A1
(en)
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
|
CN112601584A
(zh)
|
2018-07-24 |
2021-04-02 |
豪夫迈·罗氏有限公司 |
异喹啉化合物及其用途
|
|
JP7386842B2
(ja)
*
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ナフチリジン化合物およびその使用
|
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
|
MA53726A
(fr)
|
2018-09-25 |
2022-05-11 |
Incyte Corp |
Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
US11612606B2
(en)
|
2018-10-03 |
2023-03-28 |
Genentech, Inc. |
8-aminoisoquinoline compounds and uses thereof
|
|
CN113166062A
(zh)
*
|
2018-10-03 |
2021-07-23 |
豪夫迈·罗氏有限公司 |
8-氨基异喹啉化合物及其用途
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
FI3873903T3
(fi)
|
2018-10-31 |
2024-03-26 |
Gilead Sciences Inc |
Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
|
|
KR102658602B1
(ko)
*
|
2018-10-31 |
2024-04-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
|
|
US20220047603A1
(en)
|
2018-12-11 |
2022-02-17 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
TW202039481A
(zh)
|
2018-12-21 |
2020-11-01 |
美商西建公司 |
Ripk2之噻吩并吡啶抑制劑
|
|
JP7689923B2
(ja)
*
|
2018-12-26 |
2025-06-09 |
ヤンセン ファーマシューティカ エヌ．ベー． |
チエノピリジノン化合物
|
|
TW202102500A
(zh)
|
2019-03-26 |
2021-01-16 |
比利時商健生藥品公司 |
二環ｈｐｋ１抑制劑
|
|
US12492194B2
(en)
|
2019-03-26 |
2025-12-09 |
Janssen Pharmaceutica Nv |
HPK1 inhibitors
|
|
US20220242870A1
(en)
*
|
2019-05-17 |
2022-08-04 |
Voronoi Inc. |
Heterocycle-fused pyrimidine derivative and use thereof
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
TWI848141B
(zh)
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
US12459958B2
(en)
|
2019-07-17 |
2025-11-04 |
Beone Medicines I Gmbh |
Tricyclic compounds as HPK1 inhibitor and the use thereof
|
|
PE20221419A1
(es)
|
2019-08-06 |
2022-09-20 |
Incyte Corp |
Formas solidas de un inhibidor de hpk1
|
|
CN119874700A
(zh)
*
|
2019-09-13 |
2025-04-25 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
CN112552293A
(zh)
*
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
|
MX2022004370A
(es)
|
2019-10-18 |
2022-05-06 |
Forty Seven Inc |
Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
|
|
WO2021087064A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
JP7711068B2
(ja)
|
2019-12-24 |
2025-07-22 |
カルナバイオサイエンス株式会社 |
ジアシルグリセロールキナーゼ調節化合物
|
|
CN114981276B
(zh)
*
|
2020-01-09 |
2024-09-27 |
住友化学株式会社 |
杂环化合物和含有其的有害节肢动物防除组合物
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
TW202203917A
(zh)
*
|
2020-04-13 |
2022-02-01 |
加拿大健康網路大學 |
治療細胞激素釋放症候群之方法
|
|
CR20220547A
(es)
|
2020-05-01 |
2022-12-15 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina inhibidores de cd73
|
|
TW202208375A
(zh)
*
|
2020-05-11 |
2022-03-01 |
加拿大健康網路大學 |
４－胺基－５－（６－（４－甲基哌－１－基）－１ｈ－苯并［ｄ］咪唑－２－基）噻吩并［２，３－ｂ］吡啶－６（７ｈ）－酮之鹽及晶形
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
CN113845531B
(zh)
*
|
2020-06-28 |
2025-06-27 |
四川科伦博泰生物医药股份有限公司 |
吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
|
|
WO2022064458A1
(en)
*
|
2020-09-28 |
2022-03-31 |
1ST Biotherapeutics, Inc. |
Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
|
|
CN116323565A
(zh)
|
2020-09-30 |
2023-06-23 |
百济神州有限公司 |
作为hpk1抑制剂的3-[(1h-吡唑-4-基)氧基]吡嗪-2-胺化合物和其用途
|
|
WO2022098807A1
(en)
*
|
2020-11-09 |
2022-05-12 |
Merck Sharp & Dohme Corp. |
7-azole substituted 2-aminoquinazoline inhibitors of hpk1
|
|
US20240002394A1
(en)
*
|
2020-11-24 |
2024-01-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Deuterium-modified thienopyridone compound
|
|
CN114805330B
(zh)
*
|
2021-01-22 |
2026-03-10 |
苏州信诺维医药科技股份有限公司 |
Hpk1抑制剂、其制备方法、药物组合物及其应用
|
|
WO2022167627A1
(en)
|
2021-02-05 |
2022-08-11 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN114907377A
(zh)
*
|
2021-02-10 |
2022-08-16 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
US12252488B2
(en)
|
2021-02-12 |
2025-03-18 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
TW202246284A
(zh)
*
|
2021-03-10 |
2022-12-01 |
大陸商山東軒竹醫藥科技有限公司 |
三并環類hpk1抑制劑及其用途
|
|
WO2022199676A1
(zh)
*
|
2021-03-26 |
2022-09-29 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
AU2022264255A1
(en)
*
|
2021-04-30 |
2023-11-09 |
Ontario Institute For Cancer Research (Oicr) |
Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
WO2022226667A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ontario Institute For Cancer Research (Oicr) |
Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
US20240317723A1
(en)
*
|
2021-04-30 |
2024-09-26 |
Ontario Institute For Cancer Research (Oicr) |
Substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
WO2022253252A1
(en)
*
|
2021-06-03 |
2022-12-08 |
Silexon Biotech Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN115433161A
(zh)
*
|
2021-06-04 |
2022-12-06 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
EP4373817B1
(en)
|
2021-07-20 |
2025-05-21 |
Astrazeneca AB |
Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
|
|
WO2023015199A1
(en)
*
|
2021-08-03 |
2023-02-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2023023942A1
(en)
*
|
2021-08-24 |
2023-03-02 |
Biofront Ltd (Cayman) |
Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
|
|
TW202327595A
(zh)
*
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
AU2022364646B2
(en)
*
|
2021-10-15 |
2025-10-09 |
Lomond Therapeutics, Inc. |
SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
WO2023109902A1
(zh)
*
|
2021-12-17 |
2023-06-22 |
海思科医药集团股份有限公司 |
一种并环杂环衍生物及其在医药上的应用
|
|
EP4667056A1
(en)
|
2021-12-22 |
2025-12-24 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
US20250049787A1
(en)
*
|
2021-12-22 |
2025-02-13 |
University Health Network |
Treatment for acute myeloid leukemia or lymphoma
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023138612A1
(en)
*
|
2022-01-19 |
2023-07-27 |
Silexon Ai Technology Co., Ltd. |
Heterocyclic compounds useful as hpk1 inhibitors
|
|
CN118525026A
(zh)
*
|
2022-01-27 |
2024-08-20 |
西藏海思科制药有限公司 |
一种抑制或降解hpk1激酶的化合物及其在医药中的用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CN116462685B
(zh)
*
|
2022-02-08 |
2025-02-11 |
和径医药科技（上海）有限公司 |
杂环化合物、包含其的药物组合物及其抗肿瘤应用
|
|
LT4245756T
(lt)
|
2022-03-17 |
2024-11-25 |
Gilead Sciences, Inc. |
Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN117624187B
(zh)
*
|
2022-11-17 |
2025-11-04 |
杭州阿诺生物医药科技有限公司 |
一种高效的hpk1降解剂化合物及其制备方法和应用
|
|
KR102855849B1
(ko)
|
2022-11-25 |
2025-09-08 |
충남대학교산학협력단 |
이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024206869A2
(en)
*
|
2023-03-30 |
2024-10-03 |
Board Of Regents, The University Of Texas System |
Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024300557A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
KR20250053739A
(ko)
*
|
2023-10-13 |
2025-04-22 |
주식회사유한양행 |
7,7-다이메틸푸로[3,4-b]피리딘-5(7H)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
|
|
WO2025096647A1
(en)
*
|
2023-10-30 |
2025-05-08 |
Nimbus Saturn, Inc. |
Methods of treating tumors
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|